On July 4, 2016 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") reported that its pharmaceutical sales subsidiary in Mexico, Eisai Laboratorios, S. de R.L. de C.V. (Location: Mexico City, "Eisai Mexico") has launched its in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) in Mexico (Press release, Eisai, JUL 4, 2016, View Source [SID:1234513675]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Discovered at Eisai’s Tsukuba Research Laboratories and developed in-house, Lenvima is a molecular targeted agent with a novel binding mode. Lenvima is approved as a treatment for refractory thyroid cancer in over 40 countries including the United States, Japan, in Europe, South Korea and Canada. In Mexico, Lenvima was approved for treatment of locally progressive or metastatic, recurrent, radioactive iodine-refractory differentiated thyroid cancer in May 2016.

In 2014, Mexico’s pharmaceutical market was worth 11.3 billion U.S. dollars, making it the 16th biggest pharmaceutical market in the world, and the third biggest in Latin America after Brazil and Venezuela.1 In 2019, Mexico’s pharmaceutical market is expected to grow to a scale of 13.4 billion U.S. dollars.2 In August 2011, Eisai established Eisai Mexico, which currently markets the anticancer agents Halaven and Gliadel in addition to Lenvima. Eisai Mexico has also received approval for the antiepileptic agent Inovelon and submitted the antiepileptic agent Fycompa as well as the antiobesity agent lorcaserin for regulatory review.

Eisai is committed to delivering innovative new treatments to patients in Mexico while enhancing its product lineup as it seeks to further increase the benefits it provides to patients and their families in the country.

1. About Lenvima (lenvatinib mesylate)
Discovered and developed in-house, Lenvima is an orally administered multiple receptor tyrosine kinase (RTK) inhibitor with a novel binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2 and VEGFR3) and fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3 and FGFR4) in addition to other proangiogenic and oncogenic pathway-related RTKs (including the platelet-derived growth factor (PDGF) receptor PDGFRα; KIT; and RET) involved in tumor proliferation.
Currently, Eisai has obtained approval for Lenvima as a treatment for refractory thyroid cancer in over 40 countries including in the United States, Japan, in Europe, South Korea and Canada, and is undergoing regulatory review in countries throughout the world including Brazil and South Africa. Specifically, Eisai has obtained approval for the agent indicated in the United States for treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer, in Japan for the treatment of unresectable thyroid cancer, and in Europe for the treatment of adult patients with progressive, locally advanced or metastatic differentiated (papillary, follicular, Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine, respectively.
In May 2016, Lenvima was also approved for an additional indication in the United States in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. A new drug application seeking approval for an indication covering advanced or metastatic renal cell carcinoma submitted in Europe in January 2016.
Meanwhile, Eisai is conducting clinical studies of Lenvima in several other tumor types such as hepatocellular carcinoma (Phase III), endometrial carcinoma (Phase II), biliary tract cancer (Phase II), and in combination with an immune checkpoint inhibitor (Phase Ib/II).

On July 4, 2016 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) reported that its pharmaceutical sales subsidiary in Mexico, Eisai Laboratorios, S. de R.L. de C.V. (Location: Mexico City, “Eisai Mexico”) has launched its in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) in Mexico (Press release, Eisai, JUL 4, 2016, View Source [SID:1234513675]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Discovered at Eisai’s Tsukuba Research Laboratories and developed in-house, Lenvima is a molecular targeted agent with a novel binding mode. Lenvima is approved as a treatment for refractory thyroid cancer in over 40 countries including the United States, Japan, in Europe, South Korea and Canada. In Mexico, Lenvima was approved for treatment of locally progressive or metastatic, recurrent, radioactive iodine-refractory differentiated thyroid cancer in May 2016.

In 2014, Mexico’s pharmaceutical market was worth 11.3 billion U.S. dollars, making it the 16th biggest pharmaceutical market in the world, and the third biggest in Latin America after Brazil and Venezuela.1 In 2019, Mexico’s pharmaceutical market is expected to grow to a scale of 13.4 billion U.S. dollars.2 In August 2011, Eisai established Eisai Mexico, which currently markets the anticancer agents Halaven and Gliadel in addition to Lenvima. Eisai Mexico has also received approval for the antiepileptic agent Inovelon and submitted the antiepileptic agent Fycompa as well as the antiobesity agent lorcaserin for regulatory review.

Eisai is committed to delivering innovative new treatments to patients in Mexico while enhancing its product lineup as it seeks to further increase the benefits it provides to patients and their families in the country.

1. About Lenvima (lenvatinib mesylate)
Discovered and developed in-house, Lenvima is an orally administered multiple receptor tyrosine kinase (RTK) inhibitor with a novel binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2 and VEGFR3) and fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3 and FGFR4) in addition to other proangiogenic and oncogenic pathway-related RTKs (including the platelet-derived growth factor (PDGF) receptor PDGFRα; KIT; and RET) involved in tumor proliferation.
Currently, Eisai has obtained approval for Lenvima as a treatment for refractory thyroid cancer in over 40 countries including in the United States, Japan, in Europe, South Korea and Canada, and is undergoing regulatory review in countries throughout the world including Brazil and South Africa. Specifically, Eisai has obtained approval for the agent indicated in the United States for treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer, in Japan for the treatment of unresectable thyroid cancer, and in Europe for the treatment of adult patients with progressive, locally advanced or metastatic differentiated (papillary, follicular, Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine, respectively.
In May 2016, Lenvima was also approved for an additional indication in the United States in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. A new drug application seeking approval for an indication covering advanced or metastatic renal cell carcinoma submitted in Europe in January 2016.
Meanwhile, Eisai is conducting clinical studies of Lenvima in several other tumor types such as hepatocellular carcinoma (Phase III), endometrial carcinoma (Phase II), biliary tract cancer (Phase II), and in combination with an immune checkpoint inhibitor (Phase Ib/II).